体外药物敏感试验ATP-TCA在肝癌化疗中的应用  

Application of ATP base bioluminescence tumor chemosensitivity assay in the chemotherapy of hepatocellular carcinoma

作　　者：李立志[1] 郭雅[2] 黎乐群[2] 李佳荃[3] 

机构地区：[1]广西民族医院肝胆外科 [2]广西医科大学第一附属医院肝胆外科 [3]广西医科大学实验中心,广西南宁530000

出　　处：《华夏医学》2007年第3期430-432,共3页Acta Medicinae Sinica

摘　　要：目的:探讨体外三磷酸腺苷生物荧光法化疗药物敏感试验(ATP-TCA)在肝癌化疗中的应用价值。方法:用ATP-TCA法检测6种化疗药物对37例肝细胞癌标本的敏感率和耐药率。结果:37例肝癌标本中,ATP-TAC的可评估率为89.19%,6种化疗药物的敏感率分别为:更生霉素(ACTD)84.85%;长春瑞滨(NVB)78.79%;丝裂霉素C(MMC)75.76%;羟基喜树碱(HCT)42.42%;长春新碱(VCR)39.39%;吡柔比星(THP)36.36%。各试验药物的敏感率与肿瘤的大小、血清甲胎蛋白(AFP)无显著相关性(P>0.05),ACTD在P53蛋白阴性时敏感性较好,而ACTD、HCT、THP对、级肝癌的敏感率高于、级。结论:ATP-TCA法在检测肝癌化疗药物敏感性时稳定可靠,可作为肝癌化疗药物筛选的方法之一。Objective： To investigate the value and application of ATP base bioluminescence tumor chemosensitivity assay （ATP-TCA） in the chemotherapy of hepatocellular carcinoma. Methods ： Six anticancer chemotherapeutic agents were tested by using ATP-TCA with regard to cytotoxicity on treating 37 specimens of hepatocellular carcinoma resected from surgery. Results ： The outcomes of 33 in thirty-seven specimens were evaluable with an overall evaluation rate of 89.19%. The sensitivity rate of Dactinomycin （ACTD）, Vinorelbine （NVB）, Mitomycin C （MMC）, Hydroxycamptothecin （HCT）, Vincristine（VCR）, Thio-Tepa （THP） were 84. 85%, 78. 79%, 75. 76%,42. 42%, 39. 39%, 36.36%, respectively. The result of chemosensitivity assay showed no correlation with tumor＇s size and serum α-fetoprotein level. The sensitivity rate of ACTD was higher when protein p53 were negative comparing to those positive cases while which of ACTD, HCT,THP were correlatied to pathologic degree. Conclusion： ATP-TCA can be used in testing chemotherapeutic drugs against liver cancer.

关 键 词：肝细胞癌 化疗药物敏感试验 三磷酸腺苷生物荧光试验 

分 类 号：R735.7[医药卫生—肿瘤]